Background. Urinary neutrophil gelatinase-associated lipocalin (uNGAL)-associated acute kidney injury is common after liver transplantation (LT), but whether early acute kidney injury predicts chronic kidney disease (CKD) and mortality remains uncertain. Methods. Adults with LT from 2008 to 2010 in a previously published prospective cohort evaluating serial uNGAL pre-and post-LTwere retrospectively assessed to evaluate uNGAL as a predictor of long-term outcomes post-LT. The primary outcomes were post-LT CKD, defined as Modification of Diet in Renal Disease estimated glomerular filtration rate less than 60 mL/min per 1.73 m 2 for 3 continuous months, and death. Results. uNGAL at 24 hours postreperfusion was significantly higher among patients who developed CKD. Multivariable modeling for the development of CKD demonstrated that uNGAL at 24-hours postreperfusion, 24 hours post-LT renal function, initial calcineurin inhibitor, and age were independent predictors of the development of CKD at in this cohort with long-term follow-up post-LT. Further, this association was stronger in those with preserved pre-LT renal function, a population where renal outcomes are often difficult to predict. Conclusions. We propose that perioperative uNGAL may identify patients at risk for CKD and allow for targeted early implementation of renal-sparing strategies.
C hronic kidney disease (CKD) is a frequent complication of liver transplantation (LT), affecting the majority of patients who survive beyond the first 6 months.
1 CKD post-LT is associated with significant morbidity and mortality, including increased risk of cardiovascular events, 2 allograft dysfunction, 2 and death. 3 The impact of CKD on overall survival is not limited to those with end-stage renal disease, as even a decrease of 30% of the estimated glomerular filtration rate (eGFR) between 3 and 12 months after LT has been associated with significantly higher mortality rates. 4 Identifying patients at risk for CKD is critical to implement renal-sparing strategies early post-LT, as well as more intensive cardiovascular and liver allograft monitoring to improve outcomes.
To date, there is no reliable method to predict post-LT renal outcomes, especially in patients with preserved renal function at the time of LT. A number of studies have identified risk factors including preoperative creatinine, 5 diabetes mellitus (DM), 6 coronary artery disease, 6 primary graft nonfunction, 6 and hepatitis C virus (HCV) infection. 7 Further, it has been shown that acute kidney injury (AKI) immediately 8, 9 and 3 months post-LT 10 predict long-term renal outcomes. However, serum creatinine and creatinine-based equations for estimating glomerular filtration rate before and after LT are imprecise, especially in the setting of end stage liver disease or when assessing dynamic renal function in the perioperative setting. 11 Novel, more sensitive approaches to identify AKI in the perioperative setting that predict the development of post-LT CKD are needed.
Urinary neutrophil gelatinase-associated lipocalin (uNGAL), a protein expressed by injured kidney tubular epithelia, 12, 13 identifies AKI in a number of clinical scenarios, including in patients with cirrhosis and post-LT. [14] [15] [16] [17] In addition, pre-LT NGAL serum levels may be predictive of renal function in the 3 months following LT. 18 However, it remains unknown how NGAL-associated perioperative AKI impacts long-term outcomes including the development of CKD and mortality.
MATERIALS AND METHODS

Study Subjects
Adult patients undergoing LT between August 2008 and January 2010 at Columbia University Medical Center were eligible for enrollment in a previously published prospective cohort study investigating the ability of uNGAL to predict perioperative AKI. 15 Patients with preoperative renal failure requiring renal replacement therapy were excluded. In the present analysis, this cohort was retrospectively assessed for long-term renal and clinical outcomes up to 5 years post-LT. This protocol was approved by the Columbia University Institutional Review Board.
Sample Collection and Processing
In the previously described prospective cohort study, 15 urine was collected at the following time points: after induction of anesthesia before incision, immediately after portal reperfusion of the liver graft and then 3, 18, and 24 hours postreperfusion. The urine was immediately spun at 2000g and the supernatant was frozen at −80°C. uNGAL was determined using a commercially available ELISA (Antibodyshop, Gentofte, Denmark). The limit of detection for this assay is between 0.5 and 4.0 pg/mL and intra-assay variation in the urine is 2.1% (range, 1.3-4.0). 
Immunosuppression
Standard immunosuppression consisted of a calcineurin inhibitor (CNI), combined with mycophenolate and corticosteroids given as an initial bolus and then taper. Patients with significant perioperative renal insufficiency or other contraindications to CNI received basiliximab induction (n = 27) followed by delayed CNI initiation. In addition, some patients were converted to a mammalian target of rapamycin (mTOR) inhibitor (everolimus = 3 or sirolimus = 10) during the study period based on clinician judgment. This occurred after the development of CKD in most (76.9%) cases.
Statistics
The primary outcome was the development of post-LT CKD, defined as Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration rate (GFR) < 60 mL/min per 1.73 m 2 for 3 continuous months. 19 Laboratory measures of renal function were collected at listing, immediately before LT, and then monthly until death or at a minimum of 4 years post-LT. The secondary outcome was post-LT mortality. AKI was defined by the Acute Kidney Injury Network criteria 20 and by RIFLE (acronym indicating risk of renal dysfunction; injury to the kidney; failure of kidney function, loss of kidney function, and end-stage kidney disease) criteria. 21 Urine output was not captured in this study and was not included in the classification of AKI.
Continuous variables were compared between groups by t test or rank sum. Categorical variables were compared between groups by chi-square. Receiver operating characteristic (ROC) curves were generated to determine uNGAL cutoffs that maximized sensitivity and specificity. Univariable and multivariable Cox proportional-hazards models were used to evaluate relationships between perioperative uNGAL levels and time to CKD and death with a backwards elimination technique. A competing risk model was not completed for death, because each patient developed CKD before death. Variables with P values less than 0.2 were significant in univariable analysis and were considered for inclusion in multivariable models, and those not reaching significance of P less than 0.05 were sequentially eliminated. Post-LT CKD was treated as a time-varying covariate when included in models to predict post-LT mortality. Kaplan-Meier curves were generated, and log-rank tests were used to determine significance. A P value less than 0.05 was defined as significant. All analyses were performed with Stata 13.0 (College Station, TX).
RESULTS
Patient Characteristics
Ninety-two patients were enrolled in this study. The mean age was 54.4 years, 65% were male, 59% were white, and 52% had HCV (Table 1) .
Sixty-three (69%) patients developed stage 3 CKD post-LT at a median (range) of 180 (90-1080) days post-LT. Patient characteristics for those with and without CKD were generally similar between these groups. However, significant differences included a lower preoperative MDRD eGFR, older age, higher rates of HCV infection and higher body mass index (BMI) among patients who developed CKD compared with those who did not (Table 1) . Patients who developed CKD were more likely to have cyclosporine as their CNI (P < 0.001), though this may be due to high rates of cyclosporine use in patients with HCV in this period at our center. The median follow-up time was longer for those without CKD compared with patients with CKD (4.6 vs 5.1 years, respectively, P = 0.01), due to increased survival time in this group.
Eleven patients experienced CKD beyond stage 3: 7 patients reached stage 4 CKD (defined as MDRD eGFR < 30 mL/min per 1.73 m 2 ) and 4 patients progressed to stage 5 CKD (defined as MDRD eGFR < 15 mL/min per 1.73 m 2 or renal replacement therapy). Of those with stage 5 CKD, 3 patients required chronic renal replacement therapy.
Immunosuppression
Immunosuppressive regimens are summarized in Table 2 . Tacrolimus was used as the initial CNI in 56% of patients. CNI trough levels were compared between the 2 groups at 1, 6, and 12 months, 2, 3, and 4 years. There was no statistical difference between the 2 groups for either cyclosporine or tacrolimus trough levels between patients with and without CKD ( Table 2) . Twenty-five (27%) patients with significant postoperative AKI received 2 doses of basiliximab followed by delayed CNI initiation. Thirteen (14%) patients received an mTOR inhibitor (everolimus or sirolimus) at any time in the first 4 years post-LT as part of a renal protective strategy. Of these 13 patients, 10 developed stage 3 CKD before their initiation. Fortynine patients remained on dual therapy to minimize CNI at last follow-up.
Biomarkers of Peri-LT Renal Function
Median uNGAL levels pre-LT, immediately post-LT, 3 hours post-LT, 18 hours post-LT and 24 hours post-LT were compared between those who did and did not develop stage 3 CKD post-LT (Table 3) . Overall, peak There uNGAL-24 h greater than 93 ng/mL was highly specific for the development of CKD with a positive predictive value of 100%. uNGAL-24 h > 93 ng/mL significantly predicted differences in mean eGFR by 6 months post-LT (Figure 1) , as well as the development of CKD in KaplanMeier survival analysis (P < 0.01, Figure 2 ).
Perioperative GFR was significantly lower in the group that developed CKD at all time points reviewed (pre-LT, post-LT, and 24 hours post-LT). Conversely, there was no statistically significant difference in the frequency of postoperative AKI as defined by AKIN, RIFLE-R, or RIFLE-I between those who did and did not develop CKD (Table 3) . ; P < 0.01), age (HR, 1.43 per decade; P = 0.01), BMI (HR, 1.05, P = 0.01), HCV infection (HR, 3.04; P < 0.01), hepatocellular carcinoma (HCC) (HR, 2.17; P < 0.01), pre-LT hypertension (HTN) (HR, 1.72; P = 0.03), and cyclosporine as initial CNI (HR, 3.14; P < 0.01) were associated with the development of CKD (Table 4) .
In multivariable models, only uNGAL-24 h (HR, 1.09 per 100 ng/mL; P = 0.04), 24 hours post-LT MDRD eGFR (HR, 0.89 per 10 mL/min per 1.73 m 2 ; P = 0.01), cyclosporine as initial CNI (2.07, P = 0.01), and age per year (1.04, P = 0.04) remained significant predictors of CKD (Table 4) . This model was highly predictive for the development of CKD with an AUC of 0.84 (0.74-0.95) at 4 years post-LT. There was a strong correlation between pre-LT MDRD eGFR and post-LT MDRD eGFR (r = 0.77; P < 0.001) and 24 hours post-LT (r = 0.67; P < 0.001). It is likely because of this correlation that the addition of pre-LT MDRD eGFR or post-LT MDRD eGFR did not improve the accuracy of the multivariable model.
Models to Predict the Development of CKD Among Subjects With Normal Pre-LT Renal Function
Fifty patients with preserved renal function at LT were then evaluated in a subgroup analysis. Preserved pre-LT renal function was defined as preoperative GFR greater than 90 mL/min per 1.73 m 2 . In this subgroup, 28 (56%) patients developed post-LT CKD. Median NGAL levels at 24 hours PR were statistically higher in the group that developed CKD (35.3 ng/mL vs 16.0 ng/mL; P = 0.02). Additionally, in univariable modeling, an uNGAL level greater than 93 ng/mL was significantly associated with the development of CKD (HR, 4.39; P = 0.01). Similarly, a multivariable model was completed in this subgroup that demonstrated uNGAL-24 h (HR, 1.37 per 100 ng/mL; P < 0.01), HCV (HR, 4.75; P = 0.04), and age (HR, 2.24 per decade; P = 0.02) were all significant independent predictors of CKD. These findings are supported by Kaplan-Meier survival analysis that demonstrates that uNGAL-24 h greater than 93 ng/mL is associated with increased rates of CKD (P < 0.01). Conversely, pre-LT GFR was not significantly associated with the development of CKD in this population (HR, 0.98; P = 0.11).
Biomarkers of Peri-LT Renal Function to Predict Post-LT Mortality
Twenty-two (23.9%) patients died in follow up with a median time to death of 1.4 years post-LT. All patients who died in this study developed CKD before their death (P < 0.01). The causes of death included sepsis (5), HCV recurrence (3), malignancy other than HCC (3), HCC recurrence (2), cardiovascular disease (1) , and other (8) . There was no statistically significant difference in median perioperative uNGAL levels between the groups.
In ROC analysis, the AUC for uNGAL-24 h for the prediction of death at 4 years post-LT was 0.62 (0.43-0.76). uNGAL-24 h greater than 30 ng/mL significantly predicted death in Kaplan-Meier survival analysis (P = 0.04, Figure 3) .
MDRD eGFR pre-LT, post-LT, or 24 hours post-LT was not statistically different in patients who did and did not survive at a minimum of 4 years of follow-up (P = 0.55, P = 0.83, and P = 0.13, respectively). There was no statistically significant difference in the frequency of postoperative AKI as defined by AKIN, RIFLE-R, or RIFLE-I (P = 0.35, P = 0.12, and P = 0.82, respectively) between these 2 groups.
Multivariable Models to Predict Post-LT Mortality
The overall estimated 4-year survival was 79% (95% confidence interval, 70-86%). In univariable analysis, age at LT (HR, 1.78 per decade; P = 0.03), BMI (HR, 1.07; P = 0.03), HCV (HR, 5.08; P < 0.01), HCC (HR, 2.45; P = 0.04), DM after LT (HR, 3.00; P = 0.02), and HTN before LT (HR, 2.41; P = 0.04) were predictive of post-LT mortality (Table 5) . Cox regression was used to estimate the effect of a post-LT CKD on mortality. Time-dependent post-LT CKD was highly predictive of post-LT mortality (HR, 36.83; P < 0.01). In the final multivariable model, DM post-LT (HR, 2.97; P = 0.02), and time-dependent post-LT CKD (HR, 30.25; P = <0.01) remained significantly predictive of mortality. uNGAL-24 h (HR, 1.01 per 100 ng/mL; FIGURE 3. Kaplan-Meier curve for time to death by uNGAL-24 h levels. P = 0.85) was not significant in either univariable analysis or multivariable analysis.
DISCUSSION
AKI is a common and significant complication of LT.
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Urine NGAL is an established predictor of early post-LT AKI, both in the immediately postoperative setting and at 3 months. 15, 18 However, to date, no study has followed up patients beyond 3 months or studied serial NGAL measurements to determine the optimal time to measure NGAL for predictive models. In this study, we expand upon these prior observations and demonstrate the importance of prolonged urine NGAL elevation up to 24 hours postoperatively, as a marker of long-term CKD risk, especially in patients with preserved kidney function at the time of LT.
The majority of LT recipients in this cohort (69%) developed stage 3 CKD by up to 5 years post-LT, a number similar to rates previously published. 1 Despite this high rate of CKD, a minority of patients had significant AKI or CKD before transplant, as noted by median pre-LT MDRD eGFR of 83.4 and 109.4, for those who did and did not develop CKD, respectively. By excluding pre-LT AKI, uNGAL associated post-LT AKI in this study likely represents a combination of intra-operative renal injury, postoperative complications, and medication side effects.
Post-LT CKD is a strong predictor of clinical outcomes including mortality, 2 and thus, the identification of patients at risk for CKD is a priority. To date, a number of studies have identified predictors of post-LT CKD, including pre-LT eGFR, post-LT HTN, CNI-based immunosuppression, age, HCV status, and immediately post-LT eGFR. 5, 7 However, it is clear that better biomarkers of CKD risk are urgently needed to monitor patients in real time. Both creatinine and eGFR are known to be inaccurate in the setting of cirrhosis as well as with potentially dynamic kidney function in the early post-LT period. In addition, serum creatinine levels lag behind hemodynamic changes in renal function. 25 A number of biomarkers have been investigated in AKI in patients with cirrhosis, including NGAL, interleukin-18, kidney injury molecule-1, liver-type fatty acid binding protein, and albumin. 26 However, there is little data investigating these biomarkers in predicting long-term outcomes after LT. NGAL was investigated in this study because it increases rapidly after and in proportion to the degree of renal injury and may thus be ideal for the dynamic period immediately post-LT. 27 uNGAL-24 h and perioperative MDRD eGFR were the only perioperative variables in this cohort that could significantly differentiate between those who did and did not develop. Further, once a specific uNGAL-24 h threshold was reached, it could accurately predict the development of CKD. We hypothesize that uNGAL at the 24-hour time point was significant because it demonstrates the presence of persistent renal injury in the perioperative LT setting. Based on multivariable modeling, it appears that uNGAL-24 h can predict the development of CKD independent of baseline renal function; again, highlighting that uNGAL-24 h may serve as a marker of perioperative injury, rather than preexisting injury. Additionally, when those patients with preserved pre-LT renal function (MDRD eGFR > 90 mL/min per 1.73 m 2 ) were analyzed uNGAL-24 h levels were highly associated with the development of CKD (HR 4.39, P = 0.01). This is a critical finding, because renal dysfunction in patients with preserved pre-LT renal function is difficult to predict, and uNGAL may serve as a key biomarker in this population.
It is clear from prior studies that the development of CKD is associated with increased mortality after LT. 28 This cohort demonstrated a clear association between the development of CKD and mortality that was independent of other risk factors. Every patient that died during follow up developed CKD before his or her death. Lastly, it appears that an elevated uNGAL-24 h level is associated with a decreased survival; however, this association was not independent based on Cox Hazard analyses and should be validated in a larger cohort.
There are limitations of this study. Primarily, the relatively small number of patients from a single center may impact the generalizability of these findings as well as the statistical power to identify independent predictors of clinical outcomes. However, the strong consistent effect size and predictive value even in those with normal renal function support the biologic effect. In addition, creatinine-based calculations are known to be inaccurate in cirrhosis, and future studies should consider inulin clearance or cystatin C to better calculate GFR. 29 The perioperative setting is a dynamic time, making it difficult to control for all possibly confounding variables. The dataset is missing some variables that are associated with the development of CKD, namely, proteinuria. It is unknown if uNGAL will outperform this metric; we hypothesize, given its kinetics, uNGAL will better capture transient renal injury than proteinuria, but given the missing data, this remains hypothetical. Lastly, this study is retrospective and ideally would be repeated in a prospective setting.
In conclusion, uNGAL measured 24 hours post-LT appears to be an independent marker of CKD risk in the perioperative LT setting, especially in patients with preserved eGFR at the time of transplant. By accurately identifying perioperative LT renal injury, uNGAL could serve to identify patients at higher risk for CKD and trigger preemptive modifications in immunosuppressive regimen to limit nephrotoxicity or other renal-sparing strategies.
